Novartis bets big on China, 50 new drug applications expected by 2023

• The Financial Time reports that Novartis (NYSE:NVS) expects to file 50 applications for drug approvals in China by 2023, about evenly split between on-patent and off-patent medicines.
• China regulators have approved 24 of the company's drugs in the past two years. Its top seller there is leukemia med Gleevec (imatinib mesylate).
• The historical time lag from U.S. approval to China approval used to be as long as six years but now is only a matter of months.
• According to Citigroup, NVS has filed more drug applications under China's priority review system since 2016 than any other foreign firm.
• NVS drug development chief John Tsai believes that research capacity in China is approaching the U.S. while chemical identification could catch America in the next 5-10 years.

Comments

[landonne65]

Novartis is not involved in any trade war

[BAYTIME]

Swiss company neutral

[gymhog]

on the news that they're going to come out with all these new drugs out of going to be released in China wow what a stupid evaluation or any trade war remember